idea-010 · human · US
For the quantitative measurement of potassium and creatinine in fingerstick capillary whole blood by trained healthcare personnel at the point of care in outpatient clinics, as an aid in monitoring adults with chronic heart failure or chronic kidney disease during initiation and dose titration of renin-angiotensin-aldosterone system inhibitors; not for use in emergency, critical-care, or dialysis-adequacy decision-making.
Finished enough to read, and waiting for you. No department has been asked. 9 of 68 claims verified. Nobody has yet written down what it rests on.
A disposable test strip and a handheld reader that measure potassium and creatinine from a single fingerstick drop, for use by clinic staff during the visit. The problem it addresses is narrow and real: heart-failure and kidney-disease patients are put on RAAS-inhibitor drugs that have to be dose-titrated against their potassium, and today that means sending the patient for a venous blood draw and waiting for the lab, so the dose decision happens days later or not at all. The distinctive engineering choice is a third channel that does nothing but detect whether the sample was damaged during collection — a fingerstick squeezes red cells and releases potassium, which reads as a falsely high result — and suppresses the potassium value rather than reporting it. It is aimed at outpatient clinics, not emergency or dialysis settings, and would be billed through the existing clinical laboratory fee schedule rather than a new code.
In the Wrap's one-paragraph version, written for someone who has not opened the file. Domain: potassium-monitoring-ckd
Two cheques, written by two different parties, and the business only works if the second one is larger than the first. Since the last build the second cheque has a known size for one payer; the first still has no known size at all.
The chain's first link is still an assumption and its second is now half-known. Nobody has shown who buys the device. The verified CLFS rate shows what Medicare pays per test, but not whether the clinic keeps that payment, and not what running the test costs.
What this idea rests on that is not yet known, in the order this idea's own decision queue puts it: worst if false first, cheapest to settle first inside that. The first row is open; open any other for what would settle it.
This idea is unassessed, so nobody has yet named the few things it rests on. Until then, the gaps below are the rubric factors that are unscored or carry an open question. /assess idea-010 replaces this list with the real one.
Why it scored what it did: Scoreable: intended_use: is present and narrow. Rests on the Regulatory claims for 862.1600/Class II, 862.1225/Class II, product codes CEM and CGL, K070068 (an FDA 510(k) clearance number), the "no potassium predicate identified" claim, and the Dual 510(k) (premarket notification)/CLIA-waiver…the rest of this reasoning
claim. Scored on the asymmetry, not on an average. K070068 is a real-looking record and a plausible predicate for the creatinine channel only — the channel this product is not about. The potassium channel, which is the entire candidate, has no identified predicate, and the file says so outright rather than naming a placeholder. Two further discounts: the 862.1600 identification as summarised says serum, plasma and urine while this device measures capillary whole blood, which is exactly the gap a predicate argument turns on; and CEM is a lead, not a fact — the Generator's first guess (CGZ) was wrong and was chloride. Two generic types means two predicate arguments in one submission, plus the CLIA-waiver leg. A 510(k) route is plausible for half the device and entirely unresolved for the half that matters.
What would settle it: Free public checks: eCFR text for 862.1600/862.1225 and openFDA classification/510(k) lookups for product codes and predicate candidates. Still open: a human must locate and attach FDA (US Food and Drug Administration)'s Dual 510(k)/CLIA Waiver by Application guidance PDF,…the rest of this gap analysis
and confirm whether any strip-format potassium predicate exists.
Why it scored what it did: Rests on the CPT (Current Procedural Terminology) 84132 and 82565 descriptor claims, the QW-modifier claim, the CLFS economic claim, and the no-coverage-search-performed claim. The favourable half of the story — "existing codes already fit, no new code needed" — turns…the rest of this reasoning
entirely on descriptor text ("whole blood" appearing in 84132) that this pipeline can never check: CPT descriptors are AMA-licensed and connectors cpt returns unverifiable by design. Not scored as a pathway on that basis, and code existence would not be a pathway even if confirmed. The deciding question here is margin, and the file's own load-bearing claim points negative: these are Clinical Laboratory Fee Schedule codes, the allowable for a single electrolyte is low in absolute terms, and a three-channel electrochemical strip must land far below it or the clinic loses money per test. No dollar figure exists on either side of that inequality. No coverage search was performed, so coverage is an unexamined gap, not an absence of restrictions. Scored 2 = a plausible existing-code route with zero evidence of viable economics or coverage.
What would settle it: CPT descriptor and QW-modifier text need a human-attached licensed AMA source (CPT Professional or a vendor feed like Optum EncoderPro/Find-A-Code, a low annual fee). The free public CMS (Centers for Medicare & Medicaid Services) Clinical Laboratory Fee Schedule file and CLIA…the rest of this gap analysis
waived-test transmittal list settle payment rate and waiver status; strip COGS (cost of goods sold) remains a Tier 3 estimate.
Why it scored what it did: Rests on the three decomposed TAM (total addressable market) claims plus the denominator-context claim. No market number is asserted anywhere in the file — correctly so. Component 1 (Part B volume) is the only checkable-in-principle leg and it measures the wrong…the rest of this reasoning
thing: 84132 counts all potassium tests, overwhelmingly central-lab draws this device does not address, and it is a Medicare-FFS (fee-for-service) floor excluding Medicare Advantage, commercial, Medicaid, VA and cash-pay. Component 2 (price) is bounded above by an allowable that is itself unverified, so it is an assumption resting on an assumption. Component 3 (10-20% of switching clinics in five years) embeds both a switching assumption and an uncounted denominator. The 6.7M HF / 35M CKD (chronic kidney disease) figures are aggregator-grade and the file flags them as not a TAM input and not to be multiplied by anything — scored accordingly, they contribute nothing here. Held at the floor: the disease population and monitoring cadence are real, but nothing addressable is quantified.
What would settle it: The free CMS Medicare Part B (Medicare Part B) utilization PUF gives procedure volume (a floor, not TAM), and free PECOS provider-enrollment data gives the clinic denominator. Addressable share and switching rate need a licensed POC-diagnostics market…the rest of this gap analysis
report (iData or Kalorama, a paid purchase) or a commissioned practice survey.
Why it scored what it did: Rests on a single claim that states outright that no patent search was performed and no patent number is named. Scored as unexamined, not as clear — an absence of found patents is not freedom to operate. The discount is larger here…the rest of this reasoning
than the bare "no search" would imply, because the art is unusually dense: ion-selective-electrode potassium chemistry, enzymatic creatinine, and glucose-strip electrochemistry are all mature, heavily-filed fields, and the named likely estates (Nova Biomedical, Abbott Point of Care, Roche, Siemens Healthineers, i-SENS) are exactly the parties who would hold blocking claims. This deployment has no PATENTSVIEW_API_KEY, so even a named number returns unconfirmed — which would still mean "no search performed," never "no blocking art." This is the one factor whose adverse finding is an automatic kill.
What would settle it: A free CPC/assignee prior-art search in Patents Public Search or Espacenet, followed by a paid Tier 3 legal FTO (freedom to operate) opinion at Stage 7 — the opinion, not the database search, is what actually settles this factor.
Why it scored what it did: Rests on the moat claim: the defensible assets are the haemolysis detect-and-suppress logic, the potassium-selective membrane chemistry at whole-blood ionic strength, and the strip manufacturing yield curve, with the meter conceded as a…the rest of this reasoning
commodity. That is a genuine process/chemistry moat in principle — strip yield is a well-established hard-to-copy asset in glucose. Capped at 2 for two reasons the file supports: nothing is filed or even searched (Factor 1 of the moat's own legs is Factor 4, which is unexamined), and the incumbents named in the competitive claim already own high-volume strip manufacturing and ISE capability, so the yield-curve leg describes the incumbents' moat at least as well as this candidate's. The file's own read — stronger than idea-009's, weaker than a patent estate anyone has actually searched — is where this lands.
What would settle it: Resolves mostly as a by-product of the Factor 4 patent search (free). A free clearance-database scan of comparable devices gives a follower-speed pointer only, not verification; the trade-secret yield-curve leg is Tier 3 diligence with no…the rest of this gap analysis
applicable lookup.
Why it scored what it did: This is the factor that decides the candidate, and it is scored as such rather than as a footnote. Rests on the mechanism claim and its failure-mode-consequence claim, with the two clinical-premise claims as context. The clinical…the rest of this reasoning
premise is the strong part — RAASi/MRA cessation after a hyperkalemia diagnosis, and a baseline/2-week/1-month monitoring cadence that makes an in-visit result valuable — but both come from search summaries with no primary paper read, and neither is what this factor turns on. What it turns on: capillary fingerstick sampling lyses red cells, haemolysis releases intracellular potassium, and falsely elevated potassium is the named reason a strip-based fingerstick potassium meter plausibly does not already exist. This is a physical property of the sample, not an engineering defect awaiting effort. The proposed mitigation suppresses the result rather than correcting it, which trades a wrong answer for no answer — safer clinically, potentially fatal commercially. So the real performance metric is the invalid-result rate in ordinary clinic hands, not accuracy on clean samples; the file states plainly that a device voiding one draw in four is unusable however accurate it is on the rest. Not scored 3 ("plausible mechanism, needs proof"): there is no bench data, no clinical data, and no source read at all behind the central claim.
What would settle it: A free PubMed literature search for published capillary-vs-venous potassium bias and hemolysis rates is the cheapest first look and may already be decisive. The real answer is a paid Stage 7 bench study — a paired capillary-vs-venous…the rest of this gap analysis
comparison across ordinary operators with a deliberate lysis challenge — which no database substitutes for.
Why it scored what it did: Rests on the capital/time claim, which the file records as this candidate's honest principal weakness and which asserts no dollar or month figure rather than inventing one. The costs stack rather than overlap: two generic types and two…the rest of this reasoning
predicate arguments in a single submission; a Dual 510(k) plus CLIA Waiver by Application, meaning method-comparison studies at multiple untrained-operator sites; three-channel electrochemical strip development including a novel haemolysis channel; and strip manufacturing scale-up, which is a factory and a yield curve rather than a project. Time-to-revenue is further gated by the unresolved Factor 1 fork — no potassium predicate means a De Novo (De Novo classification request) and a different calendar entirely. The file's own comparison, materially slower and more capital-hungry than anything else in this portfolio, is taken at face value and scored low.
What would settle it: Depends first on Factor 1's free 510(k)-vs-De Novo resolution, then the free eCFR special-controls text for both regulations. Capex, per-site study cost, and submission cost are Tier 3 human estimates — no public source prices them.
Why it scored what it did: Low score = high intensity = unfavourable. Rests on the competitive-intensity claim (Nova Biomedical, Abbott Point of Care i-STAT, Abbott/Abaxis Piccolo, Siemens epoc) and, decisively, on the **premise-correcting claim the Generator wrote…the rest of this reasoning
against its own interest: a CLIA-waived potassium test already exists on the Piccolo Xpress waived-test list (84132QW, 82565QW). The Generator itself said that claim should cap this factor, and it is capped. The surviving gap is **form factor and per-test cost only — and the incumbents named are precisely the firms with the ISE chemistry and high-volume strip manufacturing to close a form-factor gap the moment one is shown to be closable. One point of genuine credit: no cleared strip-based fingerstick potassium meter was identified. But per Factor 6 the likelier explanation of that absence is an unsolved physical problem, not an unnoticed opportunity, so it is not scored as white space. Note also that the Generator ran no clearance scan — this is a named-firms judgement, not a measured field.
What would settle it: The free public CMS CLIA waived-test transmittal list is the cheapest item here and directly confirms or refutes whether 84132QW is actually listed. Free clearance/recall database scans give a competitive-trend pointer only; the switching…the rest of this gap analysis
question needs a licensed POC-diagnostics report or a commissioned practice survey (paid).
Why it scored what it did: No claim in this file addresses portfolio fit, so this is a shape judgement only, not evidence-backed. The shape is a hero bet, not a cash-generative spoke — the opposite of idea-008's shape: the highest capital intensity and…the rest of this reasoning
longest calendar in the portfolio by the file's own account (Factor 7), gated on an unsolved bench problem (Factor 6), against incumbents who already own the analyte (Factor 8), with an unexamined FTO field in dense art (Factor 4). Against that, the revenue shape if it works is the most durable in the portfolio — a single-use consumable consumed several times per titration episode in a chronic, recurring monitoring cadence, i.e. a razor/razorblade annuity rather than a one-off capital sale. Scored 2 conservatively because the portfolio this is meant to fit is not defined anywhere in the repo, so "fit" has no referent to score against.
What would settle it: Settled only by a Tier 3 human portfolio statement at Stage 6 review, not a database lookup. knowledge-base/calibration-log.md is the internal evidence base for this factor and is currently empty.
Seven chairs, each answering from its own field. The verdict, and the first condition it set.
Not convened. No department has stated a position on this idea yet — a normal state, not a defect. /round-table idea-010 asks all seven.
Only verified counts toward a score. A low count is usually a statement about the tooling — an absent data file, an unset key — rather than about the idea.
No claim on this idea has been refuted.
A free PubMed search for published capillary-versus-venous potassium bias and hemolysis rates, read by a human as primary sources — the Mechanism & clinical risk row's "What would settle it" column calls it "the cheapest first look" that "may already be decisive", and the feasibility deck names the same reading as the cheapest first look at its load-bearing condition claim 67unverified. It costs a search and a reader's time, it moves Factor 6, and a paid Stage 7 bench study remains the real answer behind it. This is a selection from the Scores table's gap analysis, not a new judgement and not a view about the idea.
The test this section previously named is now half done. The public CMS Clinical Laboratory Fee Schedule is on file: 84132 pays $4.76 and 82565 pays $5.12 claim 14verified. What is left of the viability condition is the cost side — an internal bill-of-materials and fully-loaded cost-per-reported-result estimate claim 36unconfirmed — which is Tier 3 human work. The viability deck notes it needs no strip to exist, no clinician interviewed and no patent searched, plus a reimbursement analyst's reading on whether a suppressed result can be billed claim 63unverified.
Only verified counts toward a score. A low count is usually a statement about the tooling (an absent data file, an unset key) rather than about the idea.
Evaluated 2026-08-25 against the Verified Composite above, using verified claims only. The Stage 2 draft table was not consulted — and pointedly so here: that draft's Factor 1 and Factor 8 narratives were superseded by the Stage 3 audit and are no longer factually current. Unchecked boxes below mean the condition did not fire, in every case because the data the condition reads does not exist yet. A condition that cannot be evaluated is not a condition that passed.
data/ cache, and it measures the wrong thing
anyway — all potassium tests, mostly central-lab draws this device cannot take. Price rests
on an unverified CLFS allowable and share is an assumption over an uncounted clinic
denominator. An undefined operand is not a low one.
PATENTSVIEW_API_KEY, and no patent number
named to search for. Zero patents were searched. Unexamined is neither clear nor
blocked, and an unexamined field cannot fire this condition — which matters, because FTO
is the rubric's only automatic kill regardless of other scores. The exposure is real
though unmeasured: ISE and glucose-strip art is mature and heavily filed by precisely the
parties who would hold blocking claims.
All three kill conditions are written over core factors — Regulatory, Reimbursement, TAM, FTO. Exactly one of those four (Regulatory, 3/5) has a verified claim behind it, and it sits above its floor. The other three are blank. The gate is not reporting that this candidate survived scrutiny; it is reporting that the scrutiny the gate performs has nothing to read. queued-research and gated-out are separated for exactly this reason: "we don't know yet" is not "the answer is no."
cpt returns unverifiable **by
design**; no connector will ever resolve it. payment and coverage hit missing caches.
And code existence would not be a pathway even if verified: the deciding question is margin
— a low CLFS allowable against a three-channel strip's COGS — with **both sides
unquantified**.
Factor 6 is blank, so the mechanism risk contributes nothing to this result — yet it is the risk that decides whether the product can exist. Hemolysis during capillary sampling falsely elevates potassium; the proposed mitigation suppresses affected results rather than correcting them, so the real metric is invalid-result rate in ordinary clinic hands, not accuracy on clean samples. No connector reaches bench physics. A Stage 0 literature scan on this question was logged to knowledge-base/signals/log.md on 2026-08-25; it carries no confidence tag, evidences nothing here, and was scored in neither direction.
Note also what the Stage 3 audit established against the candidate's own interest: the frontmatter's "no specific predicate identified for the potassium channel" is overstated. Enumerating the generic type across both product codes (CEM and MZV — the second missed by the first pass) returned 34 complete records over 30 years, including K200865 and K042270, both whole blood at point of care. What does not exist among them is one in this form factor. That is a materially weaker whitespace claim than the file asserts, and the frontmatter needs restating by the Generator.
data/ (7 claims, De Novo among them entirely
unsearched), a patent discovery sweep before any PATENTSVIEW_API_KEY is set, and — the
one that decides it — bench data on invalid-result rate, which is Stage 7 work no agent
here can do.
wrapped is not an approval — it means a human can now read this.
No human review is recorded. Shortlisting, legal and clinical sign-off and capital allocation are Tier 3: no agent in this repo makes or simulates one. The packet is wrapped, so it can be read now.
Runs only after a human shortlists the idea.
No loop record: nobody has written down what this idea rests on or convened a department on it. That is a normal state, not a defect. /front-end-loop idea-010 opens one.
Nobody has yet written down what this idea rests on and what it would cost to be wrong. Unassessed is a state, not a low score. /assess idea-010 adds it.
Click any step to see what it holds for this idea. donecurrentloopinghuman only
## Wrap section, as writtenThe one-paragraph version. A disposable test strip and a handheld reader that measure potassium and creatinine from a single fingerstick drop, for use by clinic staff during the visit. The problem it addresses is narrow and real: heart-failure and kidney-disease patients are put on RAAS-inhibitor drugs that have to be dose-titrated against their potassium, and today that means sending the patient for a venous blood draw and waiting for the lab, so the dose decision happens days later or not at all. The distinctive engineering choice is a third channel that does nothing but detect whether the sample was damaged during collection — a fingerstick squeezes red cells and releases potassium, which reads as a falsely high result — and suppresses the potassium value rather than reporting it. It is aimed at outpatient clinics, not emergency or dialysis settings, and would be billed through the existing clinical laboratory fee schedule rather than a new code.
What would have to be true, quoted verbatim from each deck's load-bearing condition (decks rebuilt 2026-09-29):
No assessment exists for idea-010, so there is no decision queue and no top-two pillars to set beside these. Unassessed is a state, not a zero — and it is the thing most worth adding before a human reads this packet.
Cheapest next test: A free PubMed search for published capillary-versus-venous potassium bias and hemolysis rates, read by a human as primary sources — the Mechanism & clinical risk row's "What would settle it" column calls it "the cheapest first look" that "may already be decisive", and the feasibility deck names the same reading as the cheapest first look at its load-bearing condition claim 67unverified. It costs a search and a reader's time, it moves Factor 6, and a paid Stage 7 bench study remains the real answer behind it. This is a selection from the Scores table's gap analysis, not a new judgement and not a view about the idea.
The test this section previously named is now half done. The public CMS Clinical Laboratory Fee Schedule is on file: 84132 pays $4.76 and 82565 pays $5.12 claim 14verified. What is left of the viability condition is the cost side — an internal bill-of-materials and fully-loaded cost-per-reported-result estimate claim 36unconfirmed — which is Tier 3 human work. The viability deck notes it needs no strip to exist, no clinician interviewed and no patent searched, plus a reimbursement analyst's reading on whether a suppressed result can be billed claim 63unverified.
Where the evidence actually stands. 9 of 68 claims verified (46 unconfirmed, 13 unverified, 0 refuted); 9 of 9 factors carrying a score; 4 of 4 core factors scored. No kill condition fired. The Verified Composite and Gate Check below are dated 2026-08-25 and predate the three claims verified on 2026-09-29 — claim 8verified (FDA's Dual 510(k) and CLIA Waiver by Application pathway, via the Federal Register), claim 14verified (CLFS-paid, $4.76 and $5.12) and claim 16verified (320,020 Medicare FFS services for 84132 and 1,160,145 for 82565, a carrier-billed Medicare floor and never a market size) claim 8verified, claim 14verified, claim 16verified. Those sections have not been rescored here; /rescore is the step that would carry these into a composite.
Most of what is still open is blocked on tooling or by design, not on a finding:
cpt is unverifiable by
design, and the HCPCS (Healthcare Common Procedure Coding System) Level II cache cannot answer Level I codes or carry modifiers
claim 11unconfirmed, claim 12unconfirmed, claim 13unconfirmed. A missing or
refused lookup here is not evidence the codes or the wording do not exist.
PATENTSVIEW_API_KEY unset, no
patent number named) claim 24unconfirmed, claim 25unconfirmed; the patent
connector now reports available in this environment, so what remains is that no search has
run — unexamined, never clear.
adoption and
market return unverifiable for exactly that reason rather than guessing
claim 28unconfirmed, claim 23unconfirmed, claim 36unconfirmed. They need
primary research, bench data and a Tier 3 cost estimate.
| Factor | Score | Why | What would settle it |
|---|---|---|---|
| Regulatory pathway | 2 | Scoreable: intended_use: is present and narrow. Rests on the Regulatory claims for 862.1600/Class II, 862.1225/Class II, product codes CEM and CGL, K070068, the "no potassium predicate identified" claim, and the Dual 510(k)/CLIA-waiver…the rest of this reasoningclaim. Scored on the asymmetry, not on an average. K070068 is a real-looking record and a plausible predicate for the creatinine channel only — the channel this product is not about. The potassium channel, which is the entire candidate, has no identified predicate, and the file says so outright rather than naming a placeholder. Two further discounts: the 862.1600 identification as summarised says serum, plasma and urine while this device measures capillary whole blood, which is exactly the gap a predicate argument turns on; and CEM is a lead, not a fact — the Generator's first guess (CGZ) was wrong and was chloride. Two generic types means two predicate arguments in one submission, plus the CLIA-waiver leg. A 510(k) route is plausible for half the device and entirely unresolved for the half that matters. | Free public checks: eCFR text for 862.1600/862.1225 and openFDA classification/510(k) lookups for product codes and predicate candidates. Still open: a human must locate and attach FDA's Dual 510(k)/CLIA Waiver by Application guidance PDF,…the rest of this gap analysisand confirm whether any strip-format potassium predicate exists. |
| Reimbursement pathway | 2 | Rests on the CPT 84132 and 82565 descriptor claims, the QW-modifier claim, the CLFS economic claim, and the no-coverage-search-performed claim. The favourable half of the story — "existing codes already fit, no new code needed" — turns…the rest of this reasoningentirely on descriptor text ("whole blood" appearing in 84132) that this pipeline can never check: CPT descriptors are AMA-licensed andconnectors cpt returns unverifiable by design. Not scored as a pathway on that basis, and code existence would not be a pathway even if confirmed. The deciding question here is margin, and the file's own load-bearing claim points negative: these are Clinical Laboratory Fee Schedule codes, the allowable for a single electrolyte is low in absolute terms, and a three-channel electrochemical strip must land far below it or the clinic loses money per test. No dollar figure exists on either side of that inequality. No coverage search was performed, so coverage is an unexamined gap, not an absence of restrictions. Scored 2 = a plausible existing-code route with zero evidence of viable economics or coverage. | CPT descriptor and QW-modifier text need a human-attached licensed AMA source (CPT Professional or a vendor feed like Optum EncoderPro/Find-A-Code, a low annual fee). The free public CMS Clinical Laboratory Fee Schedule file and CLIA…the rest of this gap analysiswaived-test transmittal list settle payment rate and waiver status; strip COGS remains a Tier 3 estimate. |
| TAM | 2 | Rests on the three decomposed TAM claims plus the denominator-context claim. No market number is asserted anywhere in the file — correctly so. Component 1 (Part B volume) is the only checkable-in-principle leg and it measures the wrong…the rest of this reasoningthing: 84132 counts all potassium tests, overwhelmingly central-lab draws this device does not address, and it is a Medicare-FFS floor excluding Medicare Advantage, commercial, Medicaid, VA and cash-pay. Component 2 (price) is bounded above by an allowable that is itself unverified, so it is an assumption resting on an assumption. Component 3 (10-20% of switching clinics in five years) embeds both a switching assumption and an uncounted denominator. The 6.7M HF / 35M CKD figures are aggregator-grade and the file flags them as not a TAM input and not to be multiplied by anything — scored accordingly, they contribute nothing here. Held at the floor: the disease population and monitoring cadence are real, but nothing addressable is quantified. | The free CMS Medicare Part B utilization PUF gives procedure volume (a floor, not TAM), and free PECOS provider-enrollment data gives the clinic denominator. Addressable share and switching rate need a licensed POC-diagnostics market…the rest of this gap analysisreport (iData or Kalorama, a paid purchase) or a commissioned practice survey. |
| FTO / IP | 1 | Rests on a single claim that states outright that no patent search was performed and no patent number is named. Scored as unexamined, not as clear — an absence of found patents is not freedom to operate. The discount is larger here…the rest of this reasoningthan the bare "no search" would imply, because the art is unusually dense: ion-selective-electrode potassium chemistry, enzymatic creatinine, and glucose-strip electrochemistry are all mature, heavily-filed fields, and the named likely estates (Nova Biomedical, Abbott Point of Care, Roche, Siemens Healthineers, i-SENS) are exactly the parties who would hold blocking claims. This deployment has noPATENTSVIEW_API_KEY, so even a named number returns unconfirmed — which would still mean "no search performed," never "no blocking art." This is the one factor whose adverse finding is an automatic kill. | A free CPC/assignee prior-art search in Patents Public Search or Espacenet, followed by a paid Tier 3 legal FTO opinion at Stage 7 — the opinion, not the database search, is what actually settles this factor. |
| Moat / defensibility | 2 | Rests on the moat claim: the defensible assets are the haemolysis detect-and-suppress logic, the potassium-selective membrane chemistry at whole-blood ionic strength, and the strip manufacturing yield curve, with the meter conceded as a…the rest of this reasoningcommodity. That is a genuine process/chemistry moat in principle — strip yield is a well-established hard-to-copy asset in glucose. Capped at 2 for two reasons the file supports: nothing is filed or even searched (Factor 1 of the moat's own legs is Factor 4, which is unexamined), and the incumbents named in the competitive claim already own high-volume strip manufacturing and ISE capability, so the yield-curve leg describes the incumbents' moat at least as well as this candidate's. The file's own read — stronger than idea-009's, weaker than a patent estate anyone has actually searched — is where this lands. | Resolves mostly as a by-product of the Factor 4 patent search (free). A free clearance-database scan of comparable devices gives a follower-speed pointer only, not verification; the trade-secret yield-curve leg is Tier 3 diligence with no…the rest of this gap analysisapplicable lookup. |
| Mechanism & clinical risk | 1 | This is the factor that decides the candidate, and it is scored as such rather than as a footnote. Rests on the mechanism claim and its failure-mode-consequence claim, with the two clinical-premise claims as context. The clinical…the rest of this reasoningpremise is the strong part — RAASi/MRA cessation after a hyperkalemia diagnosis, and a baseline/2-week/1-month monitoring cadence that makes an in-visit result valuable — but both come from search summaries with no primary paper read, and neither is what this factor turns on. What it turns on: capillary fingerstick sampling lyses red cells, haemolysis releases intracellular potassium, and falsely elevated potassium is the named reason a strip-based fingerstick potassium meter plausibly does not already exist. This is a physical property of the sample, not an engineering defect awaiting effort. The proposed mitigation suppresses the result rather than correcting it, which trades a wrong answer for no answer — safer clinically, potentially fatal commercially. So the real performance metric is the invalid-result rate in ordinary clinic hands, not accuracy on clean samples; the file states plainly that a device voiding one draw in four is unusable however accurate it is on the rest. Not scored 3 ("plausible mechanism, needs proof"): there is no bench data, no clinical data, and no source read at all behind the central claim. | A free PubMed literature search for published capillary-vs-venous potassium bias and hemolysis rates is the cheapest first look and may already be decisive. The real answer is a paid Stage 7 bench study — a paired capillary-vs-venous…the rest of this gap analysiscomparison across ordinary operators with a deliberate lysis challenge — which no database substitutes for. |
| Capital intensity & time-to-revenue | 1 | Rests on the capital/time claim, which the file records as this candidate's honest principal weakness and which asserts no dollar or month figure rather than inventing one. The costs stack rather than overlap: two generic types and two…the rest of this reasoningpredicate arguments in a single submission; a Dual 510(k) plus CLIA Waiver by Application, meaning method-comparison studies at multiple untrained-operator sites; three-channel electrochemical strip development including a novel haemolysis channel; and strip manufacturing scale-up, which is a factory and a yield curve rather than a project. Time-to-revenue is further gated by the unresolved Factor 1 fork — no potassium predicate means a De Novo and a different calendar entirely. The file's own comparison, materially slower and more capital-hungry than anything else in this portfolio, is taken at face value and scored low. | Depends first on Factor 1's free 510(k)-vs-De Novo resolution, then the free eCFR special-controls text for both regulations. Capex, per-site study cost, and submission cost are Tier 3 human estimates — no public source prices them. |
| Competitive intensity | 1 | Low score = high intensity = unfavourable. Rests on the competitive-intensity claim (Nova Biomedical, Abbott Point of Care i-STAT, Abbott/Abaxis Piccolo, Siemens epoc) and, decisively, on the **premise-correcting claim the Generator wrote…the rest of this reasoningagainst its own interest: a CLIA-waived potassium test already exists on the Piccolo Xpress waived-test list (84132QW, 82565QW). The Generator itself said that claim should cap this factor, and it is capped. The surviving gap is **form factor and per-test cost only — and the incumbents named are precisely the firms with the ISE chemistry and high-volume strip manufacturing to close a form-factor gap the moment one is shown to be closable. One point of genuine credit: no cleared strip-based fingerstick potassium meter was identified. But per Factor 6 the likelier explanation of that absence is an unsolved physical problem, not an unnoticed opportunity, so it is not scored as white space. Note also that the Generator ran no clearance scan — this is a named-firms judgement, not a measured field. | The free public CMS CLIA waived-test transmittal list is the cheapest item here and directly confirms or refutes whether 84132QW is actually listed. Free clearance/recall database scans give a competitive-trend pointer only; the switching…the rest of this gap analysisquestion needs a licensed POC-diagnostics report or a commissioned practice survey (paid). |
| Strategic fit & portfolio balance | 2 | No claim in this file addresses portfolio fit, so this is a shape judgement only, not evidence-backed. The shape is a hero bet, not a cash-generative spoke — the opposite of idea-008's shape: the highest capital intensity and…the rest of this reasoninglongest calendar in the portfolio by the file's own account (Factor 7), gated on an unsolved bench problem (Factor 6), against incumbents who already own the analyte (Factor 8), with an unexamined FTO field in dense art (Factor 4). Against that, the revenue shape if it works is the most durable in the portfolio — a single-use consumable consumed several times per titration episode in a chronic, recurring monitoring cadence, i.e. a razor/razorblade annuity rather than a one-off capital sale. Scored 2 conservatively because the portfolio this is meant to fit is not defined anywhere in the repo, so "fit" has no referent to score against. | Settled only by a Tier 3 human portfolio statement at Stage 6 review, not a database lookup. knowledge-base/calibration-log.md is the internal evidence base for this factor and is currently empty. |
All eight wrap criteria are met.
Source file: knowledge-base/candidates/idea-010.md
Nothing on this page is a recommendation. Shortlist review, legal and clinical sign-off and capital allocation are human-only decisions, and no agent in this repo may make or simulate one. This is a compilation of what the candidate file says.
_shared/plain-language.md